5-methoxy-1,1-dimethyl-2,3-dihydro-1H-indene | 1131-36-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-methoxy-1,1-dimethyl-2,3-dihydro-1H-indene
• 英文别名: 5-Methoxy-1,1-dimethylindane；6-methoxy-3,3-dimethyl-1,2-dihydroindene
• CAS: 1131-36-8
• 化学式: C₁₂H₁₆O
• 分子量: 176.258
• InChiKey: DVIQJHKQDUMLBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-methoxy-1,1-dimethyl-2,3-dihydro-1H-indene 生成 5,6,7,7a-Tetrahydro-1,1-dimethylindan-5-on
  参考文献：
  名称：

  497.萜类化合物的综合研究。第十部分。（±）-clovan-9-one和（±）-clovane的立体定向合成

  摘要：

  DOI：

  10.1039/jr9650002749
• 作为产物：
  描述：

  3-(4-甲氧基苯基)-3-甲基丁酸 在 氢氧化钾 、 磷酸 、 phosphorus pentoxide 、 一水合肼 作用下， 反应 2.0h， 生成 5-methoxy-1,1-dimethyl-2,3-dihydro-1H-indene
  参考文献：
  名称：

  497.萜类化合物的综合研究。第十部分。（±）-clovan-9-one和（±）-clovane的立体定向合成

  摘要：

  DOI：

  10.1039/jr9650002749

文献信息

• Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists
  申请人：Inoue Tadashi

  公开号：US20060100460A1

  公开（公告）日：2006-05-11

  This invention provides a compound of the formula (I): wherein R 1 represents a (C 1 -C 6 )alkyl group; R 2 represents a hydrogen atom, a halogen atom, a hydroxy group, a (C 1 -C 6 ) alkyl group or a (C 1 -C 6 ) alkoxy group; R 3 , R 4 , R 5 and R 6 each independently represents a hydrogen atom, a (C 1 -C 6 ) alkyl, or a halogen atom; R 7 represents a hydrogen atom, a halogen atom, a hydroxy group, a (C 1 -C 6 ) alkyl group optionally substituted with a piperidino group, a (C- 1 -C 6 )alkoxy group optionally substituted with a 3-7 membered cycloalkyl ring, a hydroxy(C 1 -C 6 )alkoxy group, a (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy group, a halo (C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkylthio group, a (C 1 -C 6 )alkylsulfinyl group or a (C 1 -C 6 )alkylsulfonyl group; R 5 represents a (C 1 -C 6 )alkyl group, a halo(C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkoxy group, a hydroxy(C 1 -C 6 )alkoxy group, a (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl group or a (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy group; or R 7 and R 8 , when adjacent to each other, taken together with the carbon atoms to which they are attached form a 5-8 membered carbocyclic or heterocyclic ring, wherein the carbocyclic ring or the heterocyclic ring is unsubstituted or substituted with one or more substituents selected from the group consisting of a hydroxy group, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkoxy group and a hydroxy(C 1 -C 6 )alkyl group; and R 9 represents a hydrogen atom or a halogen atom; or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor, such as pain or the like in mammalian. The present invention also provides a pharmaceutical composition comprising the compound of formula (I).

  这项发明提供了一种化合物，其化学式为（I）：其中R1代表（C1-C6）烷基基团；R2代表氢原子、卤原子、羟基、（C1-C6）烷基基团或（C1-C6）氧烷基基团；R3、R4、R5和R6分别独立地代表氢原子、（C1-C6）烷基或卤原子；R7代表氢原子、卤原子、羟基、（C1-C6）烷基基团，可选地取代有哌啶基团的（C1-C6）烷基基团，可选地取代有3-7个成员的环烷基环的（C-1-C6）氧烷基基团，羟基（C1-C6）氧烷基基团，（C1-C6）氧烷基（C1-C6）烷基基团，（C1-C6）氧烷基（C1-C6）氧烷基基团，卤代（C1-C6）烷基基团，（C1-C6）烷基硫基基团，（C1-C6）烷基亚硫基基团或（C1-C6）烷基砜基基团；R8代表（C1-C6）烷基基团，卤代（C1-C6）烷基基团，（C1-C6）氧烷基基团，羟基（C1-C6）氧烷基基团，（C1-C6）氧烷基（C1-C6）烷基基团或（C1-C6）氧烷基（C1-C6）氧烷基基团；或者R7和R8，当相邻时，与它们连接的碳原子一起形成一个5-8成员的脂环或杂环环，其中脂环或杂环环未取代或取代有一个或多个选自羟基、（C1-C6）烷基、（C1-C6）氧烷基和羟基（C1-C6）烷基的取代基；R9代表氢原子或卤原子；或其药学上可接受的盐或溶剂。这些化合物可用于治疗由VR1受体过度激活引起的疾病症状，如哺乳动物中的疼痛等。本发明还提供了一种包含化合物（I）的药物组成物。
• [EN] SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF<br/>[FR] DIHYDRO-BENZOCYCLOALKYL-OXYMÉTHYL-OXAZOLOPYRIMIDINONES SUBSTITUÉES, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：SANOFI AVENTIS

  公开号：WO2011034830A1

  公开（公告）日：2011-03-24

  The present invention relates to a series of substituted dihydro benzocycloalkyl-oxymethyl oxazolopyrimidinones of formula (I) as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, cognition deficit disorders, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

  本发明涉及一系列取代二氢苯并环烷氧甲基噁唑嘧啶酮化合物，其化学式为（I），如本文所定义。本发明还涉及制备这些化合物的方法，包括新颖的中间体。本发明的化合物是代谢型谷氨酸受体（mGluR）的调节剂，特别是mGluR2受体。因此，本发明的化合物可作为药物剂，特别是在治疗和/或预防各种中枢神经系统疾病（CNS）方面有用，包括但不限于急性和慢性神经退行性疾病、精神病、认知缺陷疾病、癫痫、焦虑、抑郁、偏头痛、疼痛、睡眠障碍和呕吐。
• Rhenium Complexes-Catalyzed Alkylation of Arenes with Alkyl Halides
  作者：Yutaka Nishiyama、Fujio Kakushou、Noboru Sonoda

  DOI：10.1246/bcsj.73.2779

  日期：2000.12

  Rhenium complexes have been shown to catalyze the alkylation of arenes with alkyl halides. When arenes were reacted with an alkyl chloride in the presence of a catalytic amount of rhenium complexes, such as bromopentacarbonylrhenium(I) [ReBr(CO)5], tricarbonylcyclopentadienylrhenium(I) [Re(C5H5)(CO)3] and decacarbonyldirhenium [Re2(CO)10], alkylation of the arenes proceeded under mild conditions to

  铼配合物已被证明可催化芳烃与烷基卤化物的烷基化。当芳烃与烷基氯在催化量的铼配合物（例如溴五羰基铼(I) [ReBr(CO)5]、三羰基环戊二烯基铼(I) [Re(C5H5)(CO)3] 和十羰基二铼）存在下反应时 [ Re2(CO)10]，芳烃的烷基化在温和条件下进行，以中等至良好的产率得到单和二烷基取代的芳烃混合物。
• Palladium-Catalyzed Alkylation with Alkyl Halides by C(sp³)−H Activation
  作者：Zhuo Wu、Ding Ma、Bo Zhou、Xiaoming Ji、Xiaotian Ma、Xiaoling Wang、Yanghui Zhang

  DOI：10.1002/anie.201706418

  日期：2017.9.25

  directing goups represents an attractive strategy for C−H functionalization. A two C−H alkylation system, initiated by the oxidative addition of organohalides to Pd0, has been developed. The first reaction involves an intermolecular alkylation of palladacycles to form C(sp3)−C(sp2) bonds followed by C(sp2)−H activation/cyclization to deliver alkylated benzocyclobutenes as the final products. In the second

  利用卤素作为无痕定向组代表了CH官能化的一种有吸引力的策略。已经开发了通过将有机卤化物氧化添加到Pd 0中而引发的两个CH烷基化系统。第一个反应涉及Palladacycles的分子间烷基化反应，形成C（sp 3）-C（sp 2）键，然后进行C（sp 2）-H活化/环化反应，以烷基化苯并环丁烯为最终产物。在第二个反应中，通过戊四环与CH 2 Br 2的反应形成两个C-C键，并提供了一种简便快捷的合成茚满酮的方法。烷基化的苯并环丁烯产物可以转化为三环烃，并且茚满衍生物是生物活性和增香剂分子中必不可少的结构基序。
• Gem-dimethyl substituted bicyclic compounds useful as eukalemic diuretics
  申请人：ICI Americas Inc.

  公开号：US04980352A1

  公开（公告）日：1990-12-25

  Certain gem-dimethyl substituted bicyclic phenolic pyrazines of formula III possess eukalemic diuretic properties. They are of value in treating those diseases and conditions in which a eukalemic diuretic effect is required, for example in treating edema, hypertension and/or related conditions.

  公式III中的某些宝石二甲基取代的双环酚基吡唑具有平衡钾利尿作用。它们在治疗需要平衡钾利尿效应的疾病和病况方面具有价值，例如在治疗水肿，高血压和/或相关病症方面。